Clinical Trial News and Research

RSS

Stem cell-based gene therapy shows long-term outcomes for treatment of genetic skin diseases

Stem cell-based gene therapy holds promise for the treatment of devastating genetic skin diseases, but the long-term clinical outcomes of this approach have been unclear.

27 Dec 2013

Scientists find inhibiting action of BRD4 protein may eradicate rare type of soft-tissue cancer

A deadly, rare type of soft-tissue cancer may be completely eradicated simply by inhibiting a key protein involved in its growth, UT Southwestern Medical Center researchers report.

27 Dec 2013

Researchers complete genomic analysis of cervical cancer in two patient populations

Researchers from the Boston area, Mexico, and Norway have completed a comprehensive genomic analysis of cervical cancer in two patient populations. The study identified recurrent genetic mutations not previously found in cervical cancer, including at least one for which targeted treatments have been approved for other forms of cancer.

25 Dec 2013

Prolonged exposure therapy shows greater success for treating adolescent PTSD patients

Researchers at Penn Medicine report in the December 25 issue of JAMA that a modified form of prolonged exposure therapy - in which patients revisit and recount aloud their trauma-related thoughts, feelings and situations - shows greater success than supportive counseling for treating adolescent PTSD patients who have been sexually abused.

25 Dec 2013

Synergy Pharmaceuticals closes patient enrollment in plecanatide phase 2b clinical trial in IBS-C

Synergy Pharmaceuticals Inc. today announced it has closed patient enrollment in its plecanatide phase 2b clinical trial in irritable bowel syndrome with constipation.

24 Dec 2013

Concordia Healthcare acquires Pinnacle Biologics

Concordia Healthcare Corp., an integrated, specialty healthcare company focused on the acquisition of legacy pharmaceutical products and medical devices and the acquisition and/or development of orphan drugs, announced today that it has acquired Pinnacle Biologics, Inc., a U.S.-based biopharmaceutical company specializing in legacy pharmaceuticals which have the potential for development as orphan drugs to treat cancer indications in addition to those for which they have previously been approved.

24 Dec 2013

Actavis' subsidiary receives FDA complete response letter for progestin-only patch NDA

Actavis plc today confirmed that the Company's subsidiary has received a complete response letter from the U.S. Food and Drug Administration for its New Drug Application for a progestin-only transdermal contraceptive patch (Norethindrone Transdermal Delivery System) for use by women to prevent pregnancy.

24 Dec 2013

Acupuncture treatments may help alleviate side effects of breast cancer drugs

A new analysis has found that both real and sham acupuncture treatments may help alleviate side effects of drugs commonly used to treat breast cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help clinicians improve care for cancer patients. The results also raise the question of whether sham acupuncture is truly inert or may, like real acupuncture, have beneficial effects.

24 Dec 2013

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

Antisense Therapeutics Limited is pleased to advise that positive results have been achieved from the interim analysis of a subset of available data from its Phase II clinical trial of ATL1103 in patients with the growth disorder, acromegaly.

23 Dec 2013

Viewpoints: Health announcement creates 'utter chaos;' a serious chip in the individual mandate; law's benefits aren't free

Last night, in a stunning reversal, the Centers for Medicare and Medicaid Services announced that Americans who have had their plans canceled will be exempt from enrolling in the exchanges, "because some consumers were finding other coverage options to be more expensive than their cancelled plans or policies."

23 Dec 2013

Scientists develop new potential cure for rare eye disease

University of British Columbia and Vancouver Coastal Health scientists have developed a potential cure for a rare eye disease, showing for the first time that a drug can repair a birth defect.

22 Dec 2013

Engineered immune cells show antitumor activity in two patients with advanced cancers

Engineered immune cells, called CARTmeso cells, designed to direct antitumor immune responses toward tumors that carry a protein called mesothelin, showed antitumor activity in two patients with advanced cancers that had not responded to prior treatments, according to a study published in Cancer Immunology Research, a journal of the American Association for Cancer Research.

22 Dec 2013

Oramed reports positive results from ORMD-0801 pharmacokinetic study in type 1 diabetes patients

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today successful results in a clinical trial testing the pharmacokinetic dose response of its oral insulin capsule (ORMD-0801) in type 1 diabetes patients.

20 Dec 2013

USC's Keck Medicine becomes world's first center to implant responsive brain device to treat epilepsy

On Dec. 18, Keck Medicine of USC became the world's first medical center to implant a responsive brain device newly approved by the Food and Drug Administration to treat epilepsy, with potential to help millions of people worldwide.

20 Dec 2013

Researchers reveal how metabolic system breaks down in obesity

Researchers at University of Michigan have illuminated an aspect of how the metabolic system breaks down in obesity. The findings provide additional evidence that a drug entering clinical trials at the university could reverse obesity, Type 2 diabetes and fatty liver disease in humans.

20 Dec 2013

Researchers discover cancer-killing properties of frankincense in ovarian cancer

Researchers from the University of Leicester have, for the first time, demonstrated the potential of treating ovarian cancer using the Christmas gift frankincense.

20 Dec 2013

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

Takeda Pharmaceutical Company Limited and Natrogen Therapeutics International, Inc. jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis.

20 Dec 2013

Blaze Bioscience to initiate first Phase 1 clinical study of BLZ-100 in patients with skin tumors

Blaze Bioscience, Inc. and its subsidiary, Blaze Bioscience Australia Pty Ltd, today announced the initiation of the first Phase 1 clinical study of the first Tumor Paint product candidate, BLZ-100. The study, titled "A Phase I Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects with Skin Cancer," will enroll up to 30 patients with basal cell carcinoma, squamous cell carcinoma, or amelanotic melanoma.

19 Dec 2013

EORTC, GIMEMA clinical trial results show high-dose cytarabine improves outcome in AML patients

Results of the EORTC and GIMEMA AML-12 Trial appearing in the Journal of Clinical Oncology show that high-dose cytarabine in induction treatment improves outcome of adult patients with acute myeloid leukemia.

19 Dec 2013

Shades of gray in QoL measures after dental whitening

A complex picture has emerged of changes in oral-health-related quality of life after at-home dental bleaching, with some measures improving and others deteriorating after the treatment, a Brazilian double-blind randomized clinical trial has shown.

19 Dec 2013

Clinical Trial News and Research

Stem cell-based gene therapy shows long-term outcomes for treatment of genetic skin diseases

Scientists find inhibiting action of BRD4 protein may eradicate rare type of soft-tissue cancer

Researchers complete genomic analysis of cervical cancer in two patient populations

Prolonged exposure therapy shows greater success for treating adolescent PTSD patients

Synergy Pharmaceuticals closes patient enrollment in plecanatide phase 2b clinical trial in IBS-C

Concordia Healthcare acquires Pinnacle Biologics

Actavis' subsidiary receives FDA complete response letter for progestin-only patch NDA

Acupuncture treatments may help alleviate side effects of breast cancer drugs

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

Viewpoints: Health announcement creates 'utter chaos;' a serious chip in the individual mandate; law's benefits aren't free

Scientists develop new potential cure for rare eye disease

Engineered immune cells show antitumor activity in two patients with advanced cancers

Oramed reports positive results from ORMD-0801 pharmacokinetic study in type 1 diabetes patients

USC's Keck Medicine becomes world's first center to implant responsive brain device to treat epilepsy

Researchers reveal how metabolic system breaks down in obesity

Researchers discover cancer-killing properties of frankincense in ovarian cancer

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

Blaze Bioscience to initiate first Phase 1 clinical study of BLZ-100 in patients with skin tumors

EORTC, GIMEMA clinical trial results show high-dose cytarabine improves outcome in AML patients

Shades of gray in QoL measures after dental whitening

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer